Roles of the kinase TAK1 in TRAF6-dependent signaling by CD40 and its oncogenic viral mimic, LMP1

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Arcipowski, Kelly M ^a   Bishop, Gail A ^b,c  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 7 OXOZEAENOL; CD40 ANTIGEN; INTERLEUKIN 6; LATENT MEMBRANE PROTEIN 1; PROTEIN SERINE THREONINE KINASE INHIBITOR; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD40; BIOMIMETICS; HUMANS; MAP KINASE KINASE KINASES; MICE; SIGNAL TRANSDUCTION; TNF RECEPTOR-ASSOCIATED FACTOR 6;

HUMAN HERPESVIRUS 4;

EID: 84864447485     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042478     Document Type: Article

References (71)

1. Küppers R, (2003) B cells under influence: transformation of B cells by EBV. Nat Rev Immunol 3: 801-812.
2. Busch LK, Bishop GA, (1999) The EBV transforming protein, LMP1, mimics and cooperates with CD40 signaling in B lymphocytes. J Immunol 162: 2555-2561.
3. Pai S, Khanna R, (2001) Role of LMP1 in immune control of EBV infection. Semin Cancer Biol 11: 455-460.
4. Schubert S, Abdul-Khaliq H, Lehmkuhl HB, Yegitbasi M, Reinke P, et al. (2009) Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients. Pediatr Transplant 13: 54-62.
5. Yin Q, Wang X, McBride J, Fewell C, Flemington E, (2008) B-cell receptor activation induces BIC/miR-155 expression through a conserved AP-1 element. J Biol Chem 283: 2654-2662.
6. Eliopoulos AG, Young LS, (2001) LMP1 structure and signal transduction. Semin Cancer Biol 11: 435-444.
7. Thorley-Lawson DA, (2001) EBV: exploiting the immune system. Nat Rev Immunol 1: 75-82.
8. Adam P, Bonzheim I, Fend F, Quintanilla-Martinez L, (2011) Epstein-Barr virus-positive diffuse large B-cell lymphomas of the elderly. Adv Anat Pathol 18: 349-355.
9. Abou-Raya A, Abou-Raya S, (2006) Inflammation: a pivotal link between autoimmune diseases and atherosclerosis. Autoimmunity Rev 5: 331-337.
10. Gross AJ, Hochberg D, Rand WM, Thorley-Lawson DA, (2005) EBV and systemic lupus erythematosus: a new perspective. J Immunol 174: 6599-6607.
11. Bishop GA, Busch LK, (2002) Molecular mechanisms of B lymphocyte transformation by Epstein-Barr virus. Microbes Infect 4: 853-857.
12. Arcipowski KM, Stunz LL, Graham JP, Kraus ZJ, Vanden Bush TJ, et al. (2011) Molecular mechanisms of TNFR-associated factor 6 (TRAF6) utilization by the oncogenic viral mimic of CD40, latent membrane protein 1 (LMP1). J Biol Chem 286: 9948-9955.
13. Poole BD, Templeton AK, Guthridge JM, Brown EJ, Harley JB, et al. (2009) Aberrant Epstein-Barr viral infection in systemic lupus erythematosus. Autoimmunity Rev 8: 337-342.
14. Peters AL, Stunz LL, Meyerholz DK, Mohan C, Bishop GA, (2010) Latent Membrane Protein 1, the EBV-encoded oncogenic mimic of CD40, accelerates autoimmunity in B6.Sle1 mice. J Immunol pp. 10.4049/jimmunol.0904065.
15. Wu S, Xie P, Welsh K, Li C, Ni C, et al. (2005) LMP1 protein from EBV is a structural decoy in B lymphocytes for binding to TRAF3. J Biol Chem 280: 33620-33626.
16. Xie P, Bishop GA, (2004) Roles of TRAF3 in signaling to B lymphocytes by CTAR regions 1 and 2 of the EBV-encoded oncoprotein LMP1. J Immunol 173: 5546-5555.
17. Schultheiss U, Püschner S, Kremmer E, Mak TW, Engelmann H, et al. (2001) TRAF6 is a critical mediator of signal transduction by the viral oncogene LMP1. EMBO J 20: 5678-5691.
18. Xie P, Hostager BS, Bishop GA, (2004) Requirement for TRAF3 in signaling by LMP1, but not CD40, in B lymphocytes. J Exp Med 199: 661-671.
19. Wu L, Nakano H, Wu Z, (2006) The CTAR2 of the EBV-encoded LMP1 activates NF-kB through TRAF6 and TAK1. J Biol Chem 281: 2162-2169.
20. Brown KD, Hostager BS, Bishop GA, (2001) Differential signaling and TRAF degradation by CD40 and the EBV oncoprotein LMP1. J Exp Med 193: 943-954.
21. Graham J, Moore C, Bishop G, (2009) Roles of the TRAF2/3 binding site in differential B cell signaling by CD40 and its viral oncogenic mimic, LMP1. J Immunol 183: 2966-2973.
22. Kraus ZJ, Nakano H, Bishop GA, (2009) TRAF5 is a critical mediator of in vitro signals and in vivo functions of LMP1, the viral oncogenic mimic of CD40. Proc Natl Acad Sci USA 106: 17140-17145.
23. Stunz LL, Busch LK, Munroe ME, Tygrett L, Sigmund C, et al. (2004) Expression of the LMP1 cytoplasmic tail in mice induces hyperactivation of B lymphocytes and disordered lymphoid architecture. Immunity 21: 255-266.
24. Graham JP, Arcipowski KM, Bishop GA, (2010) Differential B lymphocyte regulation by CD40 and its viral mimic, latent membrane protein 1. Immunol Rev 237: 226-248.
25. Busch LK, Bishop GA, (2001) Multiple carboxyl-terminal regions of the EBV oncoprotein, LMP1, cooperatively regulate signaling to B lymphocytes via TRAF-dependent and TRAF-independent mechanisms. J Immunol 167: 5805-5813.
26. Xie P, Hostager BS, Munroe ME, Moore CR, Bishop GA, (2006) Cooperation between TNF receptor-associated factors 1 and 2 in CD40 signaling. J Immunol 176: 5388-5400.
27. Bradley JR, Pober JS, (2001) Tumor necrosis factor receptor-associated factors (TRAFs). Oncogene 20: 6482-6491.
28. Nakano H, Sakon S, Koseki H, Takemori T, Tada K, et al. (1999) Targeted disruption of Traf5 gene causes defects in CD40- and CD27-mediated lymphocyte activation. Proc Natl Acad Sci USA 96: 9803-9808.
29. Rowland SR, Tremblay ML, Ellison JM, Stunz LL, Bishop GA, et al. (2007) A novel mechanism for TRAF6-dependent CD40 signaling. J Immunol 179: 4645-4653.
30. Kim SI, Kwak JH, Zachariah M, He Y, Wang L, et al. (2007) TGF-beta-activated kinase 1 and TAK1-binding protein 1 cooperate to mediate TGF-beta1-induced MKK3-p38 MAPK activation and stimulation of type I collagen. Am J Physiol Renal Physiol 292: F1471-1478.
31. Ninomiya-Tsuji J, Kajino T, Ono K, Ohtomo T, Matsumoto M, et al. (2003) A resorcylic acid lactone, 5Z-7-oxozeaenol, prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase. J Biol Chem 278: 18485-18490.
32. Kishimoto K, Matsumoto K, Ninomiya-Tsuji J, (2000) TAK1 mitogen-activated protein kinase kinase kinase is activated by autophosphorylation within its activation loop. J Biol Chem 275: 7359-7364.
33. Yamaguchi K, Shirakabe K, Shibuya H, Irie K, Oishi I, et al. (1995) Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science 270: 2008-2011.
34. Sakurai H, Miyoshi H, Mizukami J, Sugita T, (2000) Phosphorylation-dependent activation of TAK1 mitogen-activated protein kinase kinase kinase by TAB1. FEBS Lett 474: 141-145.
35. Singh A, Sweeney MF, Yu M, Burger A, Greninger P, et al. (2012) TAK1 Inhibition Promotes Apoptosis in KRAS-Dependent Colon Cancers. Cell 148: 639-650.
36. Melisi D, Xia Q, Paradiso G, Ling J, Moccia T, et al. (2011) Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. J Natl Cancer Inst 103: 1190-1204.
37. Martin SE, Wu ZH, Gehlhaus K, Jones TL, Zhang YW, et al. (2011) RNAi screening identifies TAK1 as a potential target for the enhanced efficacy of topoisomerase inhibitors. Curr Cancer Drug Targets 11: 976-986.
38. Safina A, Sotomayor P, Limoge M, Morrison C, Bakin AV, (2011) TAK1-TAB2 signaling contributes to bone destruction by breast carcinoma cells. Mol Cancer Res 9: 1042-1053.
39. Omori E, Matsumoto K, Zhu S, Smart RC, Ninomiya-Tsuji J, (2010) Ablation of TAK1 upregulates reactive oxygen species and selectively kills tumor cells. Cancer Res 70: 8417-8425.
40. Sato S, Sanjo H, Takeda K, Ninomiya-Tsuji J, Yamamoto M, et al. (2005) Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat Immunol 6: 1087-1095.
41. Uemura N, Kajino T, Sanjo H, Sato S, Akira S, et al. (2006) TAK1 is a component of the Epstein-Barr virus LMP1 complex and is essential for activation of JNK but not of NF-kappaB. J Biol Chem 281: 7863-7872.
42. Xie P, Poovassery J, Stunz LL, Smith SM, Schultz ML, et al. (2011) Enhanced Toll-like receptor (TLR) responses of TNFR-associated factor 3 (TRAF3)-deficient B lymphocytes. J Leukoc Biol 90: 1149-1157.
43. Kobayashi T, Walsh MC, Choi Y, (2004) The role of TRAF6 in signal transduction and the immune response. Microbes Infect 6: 1333-1338.
44. Jalukar SV, Hostager BS, Bishop GA, (2000) Characterization of the roles of TNF receptor-associated factor 6 in CD40-mediated B lymphocyte effector functions. J Immunol 164: 623-630.
45. Bishop GA, Hostager BS, Brown KD, (2002) Mechanisms of tumor necrosis factor receptor associated factor (TRAF) regulation in B lymphocytes. J Leukocyte Biol 72: 19-23.
46. Holtmann H, Enninga J, Kalble S, Thiefes A, Dorrie A, et al. (2001) The MAPK kinase kinase TAK1 plays a central role in coupling the interleukin-1 receptor to both transcriptional and RNA-targeted mechanisms of gene regulation. J Biol Chem 276: 3508-3516.
47. Ninomiya-Tsuji J, Kishimoto K, Hiyama A, Inoue J, Cao Z, et al. (1999) The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature 398: 252-256.
48. Baccam M, Bishop GA, (1999) Membrane-bound CD154, but not CD40-specific antibody, mediates NF-kappaB-independent IL-6 production in B cells. Eur J Immunol 29: 3855-3866.
49. Vanden Bush TJ, Bishop GA, (2011) CDK-mediated regulation of cell functions via c-Jun phosphorylation and AP-1 activation. PLoS ONE 6: e19468.
50. Baccam M, Woo SY, Vinson C, Bishop GA, (2003) CD40-mediated transcriptional regulation of the IL-6 gene in B lymphocytes: involvement of NF-kappa B, AP-1, and C/EBP. J Immunol 170: 3099-3108.
51. Hammaker DR, Boyle DL, Chabaud-Riou M, Firestein GS, (2004) Regulation of c-Jun N-terminal kinase by MEKK-2 and mitogen-activated protein kinase kinase kinases in rheumatoid arthritis. J Immunol 172: 1612-1618.
52. Ip YT, Davis RJ, (1998) Signal transduction by the c-Jun N-terminal kinase (JNK)-from inflammation to development. Curr Opin Cell Biol 10: 205-219.
53. Vanden Bush TJ, Bishop GA, (2008) TLR7 and CD40 cooperate in IL-6 production via enhanced JNK and AP-1 activation. Eur J Immunol 38: 400-409.
54. Schuman J, Chen Y, Podd A, Yu M, Liu HH, et al. (2009) A critical role of TAK1 in B-cell receptor-mediated nuclear factor kappaB activation. Blood 113: 4566-4574.
55. Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M, (2012) IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond) 122: 143-159.
56. Tanaka T, Narazaki M, Kishimoto T, (2011) Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. FEBS Lett 585: 3699-3709.
57. Chalaris A, Garbers C, Rabe B, Rose-John S, Scheller J, (2011) The soluble interleukin 6 receptor: generation and role in inflammation and cancer. Eur J Cell Biol 90: 484-494.
58. Liu HH, Xie M, Schneider MD, Chen ZJ, (2006) Essential role of TAK1 in thymocyte development and activation. Proc Natl Acad Sci U S A 103: 11677-11682.
59. Tseng PH, Matsuzawa A, Zhang W, Mino T, Vignali DA, et al. (2010) Different modes of ubiquitination of the adaptor TRAF3 selectively activate the expression of type I interferons and proinflammatory cytokines. Nat Immunol 11: 70-75.
60. Peters AL, Bishop GA, (2010) Differential TRAF3 utilization by a variant human CD40 receptor with enhanced signaling. J Immunol 185: 6555-6562.
61. Pullen SS, Dang TT, Crute JJ, Kehry MR, (1999) CD40 signaling through tumor necrosis factor receptor-associated factors (TRAFs). Binding site specificity and activation of downstream pathways by distinct TRAFs. J Biol Chem 274: 14246-14254.
62. Hostager BS, Catlett IM, Bishop GA, (2000) Recruitment of CD40 and tumor necrosis factor receptor-associated factors 2 and 3 to membrane microdomains during CD40 signaling. J Biol Chem 275: 15392-15398.
63. Bishop GA, (2004) The multifaceted roles of TRAFs in the regulation of B cell function. Nat Rev Immunol 4: 775-786.
64. Pullen SS, Miller HG, Everdeen DS, Dang TT, Crute JJ, et al. (1998) CD40-tumor necrosis factor receptor-associated factor (TRAF) interactions: regulation of CD40 signaling through multiple TRAF binding sites and TRAF hetero-oligomerization. Biochemistry 37: 11836-11845.
65. Dietz AB, Bulur PA, Emery RL, Winters JL, Epps DE, et al. (2006) A novel source of viable peripheral blood mononuclear cells from leukoreduction system chambers. Transfusion 46: 2083-2089.
66. Bishop GA, Haughton G, (1986) Induced differentiation of a transformed clone of Ly-1+ B cells by clonal T cells and antigen. Proc Natl Acad Sci USA 83: 7410-7414.
67. Kim KJ, Kanellopoulos-Langevin C, Merwin RM, Sachs DH, Asofsky R, (1979) Establishment and characterization of BALB/c lymphoma lines with B cell properties. J Immunol 122: 549-554.
68. Hostager BS, Hsing Y, Harms DE, Bishop GA, (1996) Different CD40-mediated signaling events require distinct CD40 structural features. J Immunol 157: 1047-1053.
69. Warren WD, Berton MT, (1995) Induction of germ-line gamma 1 and epsilon Ig gene expression in murine B cells. IL-4 and the CD40 ligand-CD40 interaction provide distinct but synergistic signals. J Immunol 155: 5637-5646.
70. Bishop GA, Warren WD, Berton MT, (1995) Signaling via major histocompatibility complex class II molecules and antigen receptors enhances the B cell response to gp39/CD40 ligand. Eur J Immunol 25: 1230-1238.
71. Bishop GA, (1991) Requirements of class II-mediated B cell differentiation for class II cross-linking and cyclic AMP. J Immunol 147: 1107-1114.